

To: (10)(2e) (10)(2e)@rivm.nl]
From: (10)(2e)
Sent: Tue 6/2/2020 3:15:52 PM
Subject: RE: Melding nr. M2005 9963 onderwerp: COVID-19 study
Received: Tue 6/2/2020 3:15:53 PM

Dank je (10)(2e)

From: (10)(2e) <(10)(2e)@rivm.nl>
Sent: dinsdag 2 juni 2020 16:51
To: Info-RIVM <info@rivm.nl>
Cc: (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@rivm.nl>
Subject: FW: Melding nr. M2005 9963 onderwerp: COVID-19 study

Beste (10)(2e)

Hierbij vind je een korte beschrijving van de opzet van de studie. De opzet van de oorspronkelijke studie is gepubliceerd (zie hieronder; Verberk et al.). Personen die daarvoor toestemming hebben gegeven destijds (om op nieuw benaderd te mogen worden), hebben we gevraagd deel te nemen aan seroprevalentie onderzoek naar COVID-19. Overigens zijn we momenteel de studie aan het uitbreiden; we nodigen nu nieuwe personen uit die ook vragen vingerprik af te nemen en vragenlijst in te vullen.

Groet (10)(2e)


In 2016/2017, a third large-scale seroprevalence study (PIENTER-3) was initiated among a representative part of the Dutch population (n=7,600; age-range 0-89 years; 40 municipalities nationwide and 9 municipalities with low vaccination coverage (LVC) enrolled via a two-stage cluster technique). A comprehensive description of PIENTER-3 has been published previously (1). Briefly, the primary aim of that study was to obtain insight in the protection against infectious diseases for which vaccines are offered by the national immunization program in the Netherlands. Among other materials, sera and questionnaire data had been collected from all participants. Hence, the PIENTER-3 study offered an unique opportunity as baseline sample of the Dutch population for the present study (PIENTER-Corona) since 6,102 participants (80%) gave consent to be approached for follow-up (after screening on validity of the address and possible death).

The invitation letter was sent to previous PIENTER-3 study participants by the National Institute for Public Health and the Environment of the Netherlands (RIVM) on 25 March 2020. Invitees (age-range 2-93 years) who were willing to participate on different timepoints during the course of the COVID-19 epidemic (with intervals of 2-3 months) could register online. They were sent an informed consent form as well as medical equipment and information on how to self-collect a fingerstick blood sample in a microtainer (maximum of 0.5 mL) at home quickly after enrollment. Written informed consent forms (from all participants aged > 11 years and from parents/legal representatives of those < 16 years of age) and blood samples were sent back to the RIVM laboratory in safety envelopes. Blood samples were aliquoted and stored at -80 °C until analyses. Participants were asked to complete an online questionnaire on the same day as the blood collection. This study protocol was approved by the Medical Ethics Committee (Clinical Trial Registration NTR8473).

References

1. Verberk JDM, Vos RA, Mollma L, van Vliet J, van Weert JWM, de Melker HE, et al. Third national biobank for population-based seroprevalence studies in the Netherlands, including the Caribbean Netherlands. *BMC infectious diseases*. 2019;19(1):470.

(10)(2e) (10)(2e)
 (10)(2e) (10)(2e) (10)(2e) (10)(2e)
 (10)(2e) (10)(2e) (10)(2e)



(10)(2e)

Dubbel